AI Article Synopsis

  • * Approximately half of E-GBM cases show genetic alterations such as BRAF V600E, TERT promoter mutations, and CDKN2A/B deletions, which are also found in lower-grade glioma components when present.
  • * A study analyzed 14 E-GBM cases, revealing that genetic changes commonly found in lower-grade lesions also occur in E-GBM, indicating a close relationship between the two and suggesting a shared molecular background.

Article Abstract

Epithelioid glioblastoma (E-GBM) is a rare aggressive variant of IDH-wildtype glioblastoma newly recognized in the 2016 World Health Organization classification, composed predominantly of monotonous, patternless sheets of round cells with laterally positioned nuclei and plump eosinophilic cytoplasm. Approximately 50% of E-GBM harbor BRAF V600E, which is much less frequently found in other types of glioblastomas. Most E-GBM are recognized as primary/de novo lesions; however, several E-GBM with co- or pre-existing lower-grade lesions have been reported. To better understand associations between E-GBM and the lower-grade lesions, we undertook a histological and molecular analysis of 14 E-GBM, 10 of which exhibited lower-grade glioma-like components (8 E-GBM with co-existing diffuse glioma-like components, 1 E-GBM with a co-existing PXA-like component and 1 E-GBM with a pre-existing PXA). Molecular results demonstrated that the prevalence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions in E-GBM were 13/14 (93%), 10/14 (71%) and 11/14 (79%), respectively, and concurrent BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions were observed in 7/14 (50%) of E-GBM. These alterations were also frequently seen in the lower-grade lesions irrespective of the histology. Genetic analysis including array comparative genomic hybridization performed for 5 E-GBM with co- and pre-existing lower-grade components revealed that all molecular changes found in the lower-grade components were also observed in the E-GBM components, and additional changes were detected in the E-GBM components. In conclusion, E-GBM frequently exhibit BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions and these alterations tend to coexist in E-GBM. Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028676PMC
http://dx.doi.org/10.1111/bpa.12572DOI Listing

Publication Analysis

Top Keywords

braf v600e
24
v600e tert
20
tert promoter
20
promoter mutations
20
mutations cdkn2a/b
20
cdkn2a/b homozygous
20
homozygous deletions
20
e-gbm
18
lower-grade lesions
16
glioma-like components
12

Similar Publications

BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAF (mutant) papillary thyroid carcinoma progression and sorafenib resistance.

Int J Biol Sci

January 2025

Department of Thyroid and Hernia Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou City, Fujian Province 350001, China.

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and patients with the BRAF mutation often exhibit aggressive tumor behavior. Here, we identified Arylsulfatase I (ARSI) as a gene whose expression was significantly upregulated in BRAF PTC and was associated with poor prognosis. High ARSI expression correlated with advanced disease stage, BRAF mutation, and worse overall survival in PTC patients.

View Article and Find Full Text PDF

[Correlation of Mutation with Clinical Features and Prognosis of Langerhans Cell Histiocytosis in Cildren].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China.

Objective: To explore the gene mutations of Langerhans cell histiocytosis in children, and to analyze the correlation of mutation with clinical features and prognosis of LCH, so as to provide reference for clinical diagnosis and treatment.

Methods: Fluorescence PCR was used to detect gene mutations in paraffin-embedded tissue samples from 78 children with LCH, and the correlation of mutation with clinical characteristics and prognosis of LCH in children was analyzed.

Results: Among the 78 children, 41 cases (52.

View Article and Find Full Text PDF
Article Synopsis
  • Colorectal cancer is the third most common cancer, and managing unresectable metastatic cases, especially those with MSS and BRAF V600E mutation, poses significant challenges for treatment.
  • Two case reports illustrate the effectiveness of an alternating chemotherapy regimen (irinotecan and oxaliplatin along with capecitabine and bevacizumab) in two patients with MSS, BRAF V600E-mutated stage IV metastatic CRC, demonstrating a partial response and dropping carcinoembryonic antigen levels.
  • The study suggests that this alternating regimen offers a promising treatment strategy with improved progression-free survival compared to standard first-line therapies, making it a potential first-line option for patients with this specific type of colorectal cancer.
View Article and Find Full Text PDF

Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.

Mol Diagn Ther

December 2024

Comprehensive Cancer Center, University of Maastricht, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.

Introduction: Anorectal melanoma is a rare neoplasm with an aggressive behavior and poor prognosis. Recently, recurrent gene mutations related to anorectal melanoma have been identified in a small series of cases, and this holds promise for targeted therapies, analogous to cutaneous melanoma. The purpose of this study was to analyze testing rates and prevalence of mutations in anorectal melanoma in the Dutch population.

View Article and Find Full Text PDF

Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are exceptionally rare disorders characterized by varied clinical presentations, posing several challenges for clinicians. The concomitant occurrence of LCH and ECD is exceedingly rare and has no known etiology. In this report, we present a rare case of mixed histiocytosis (both ECD and LCH) with multisystem involvement.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!